We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Archrock
AROC
$5.78B
| $1.86M | ﹤0.01% |
225,445
+7,126
| +3% | +$65.3K |
|
1127
Virtus Investment Partners
VRTS
$1.11B
| $1.86M | ﹤0.01% |
10,895
+2,433
| +29% | +$459K |
|
1128
National Healthcare
NHC
$3.39B
| $1.86M | ﹤0.01% |
26,566
-1,905
| -7% | -$133K |
|
|
UNIT
1129
Uniti Group
UNIT
$2.25B
| $1.86M | ﹤0.01% |
197,046
+43,213
| +28% | +$500K |
|
1130
AdvanSix
ASIX
$452M
| $1.85M | ﹤0.01% |
55,401
+7,828
| +16% | +$349K |
|
|
ESGR
1131
DELISTED
Enstar Group
ESGR
| $1.85M | ﹤0.01% |
8,659
-1,692
| -16% | -$393K |
|
1132
Heritage Financial
HFWA
$1.21B
| $1.85M | ﹤0.01% |
73,604
+6,685
| +10% | +$167K |
|
1133
Barrett Business Services
BBSI
$761M
| $1.85M | ﹤0.01% |
101,312
+12,556
| +14% | +$231K |
|
1134
Primerica
PRI
$9.63B
| $1.84M | ﹤0.01% |
15,712
+2,950
| +23% | +$371K |
|
|
SAGE
1135
DELISTED
Sage Therapeutics
SAGE
| $1.83M | ﹤0.01% |
57,723
-274,023
| -83% | -$9.18M |
|
1136
MarketAxess Holdings
MKTX
$5.72B
| $1.83M | ﹤0.01% |
7,137
+260
| +4% | +$71.1K |
|
1137
G-III Apparel Group
GIII
$1.44B
| $1.83M | ﹤0.01% |
90,279
+41,032
| +83% | +$1.04M |
|
1138
ONE Gas
OGS
$5B
| $1.83M | ﹤0.01% |
22,569
+3,443
| +18% | +$295K |
|
1139
Oppenheimer Holdings
OPY
$1.21B
| $1.83M | ﹤0.01% |
55,263
+18,943
| +52% | +$651K |
|
1140
Patterson-UTI
PTEN
$4.22B
| $1.82M | ﹤0.01% |
115,741
-54,956
| -32% | -$923K |
|
1141
NBT Bancorp
NBTB
$2.75B
| $1.82M | ﹤0.01% |
48,450
+10,536
| +28% | +$382K |
|
|
SWN
1142
DELISTED
Southwestern Energy Company
SWN
| $1.81M | ﹤0.01% |
290,464
-27,056
| -9% | -$209K |
|
1143
Moog Inc Class A
MOG.A
$13.2B
| $1.81M | ﹤0.01% |
22,844
+18,104
| +382% | +$1.47M |
|
1144
Titan International
TWI
$461M
| $1.81M | ﹤0.01% |
119,856
-29,053
| -20% | -$469K |
|
|
AVID
1145
DELISTED
Avid Technology Inc
AVID
| $1.81M | ﹤0.01% |
69,655
-1,203
| -2% | -$35.1K |
|
|
AVNS
1146
DELISTED
Avanos Medical
AVNS
| $1.8M | ﹤0.01% |
67,319
+11,770
| +21% | +$338K |
|
1147
ESAB
ESAB
$5.47B
| $1.8M | ﹤0.01% |
+41,160
| New | +$1.99M |
|
1148
OFG Bancorp
OFG
$2.22B
| $1.78M | ﹤0.01% |
70,229
-1,585
| -2% | -$42.5K |
|
1149
Arcus Biosciences
RCUS
$3.66B
| $1.78M | ﹤0.01% |
+70,333
| New | +$1.72M |
|
1150
Red Rock Resorts
RRR
$3.73B
| $1.77M | ﹤0.01% |
53,039
+9,357
| +21% | +$374K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.